Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Acarbose Clear all
Completed Phase 1 Interventional

Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

NCT02685852
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia
Interventions
Exenatide, Acarbose, Exenatide Placebo, Acarbose Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 2, 2026, 5:42 AM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia

NCT04877366
View directory record Official record
Conditions
Dietary Supplement
Interventions
Dietary Supplement: Sprinkled Format REDUCOSE., Reference control, Active comparator
Dietary Supplement · Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Efficacy and Tolerability of Acarbose in Healthy Individuals

NCT05542849
View directory record Official record
Conditions
Tolerance, Side Effect, Glucose Response
Interventions
Acarbose Tablets 50mg
Drug
Lead sponsor
AgelessRx
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2 Interventional

Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.

NCT01839344
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Quercetin, Acarbose, placebo
Dietary Supplement · Drug
Lead sponsor
Bastyr University
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 4 Interventional

Early Diabetes Intervention Program

NCT01470937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Acarbose, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
25 Years to 80 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Sep 2, 2026, 5:42 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of Acarbose in Longevity

NCT02953093
View directory record Official record
Conditions
Aging
Interventions
Acarbose, Placebo
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
60 Years to 100 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 2, 2026, 5:42 AM EDT
Completed No phase listed Observational

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

NCT03492580
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
714,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Human Oral Detection of Glucose Olygomers

NCT02589353
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acarbose
Drug
Lead sponsor
Oregon State University
Other
Eligibility
18 Years to 60 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 2, 2026, 5:42 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity

NCT00846521
View directory record Official record
Conditions
Pediatric Obesity, Insulin Resistance, Impaired Glucose Tolerance, Cardiovascular Disease
Interventions
Acarbose
Drug
Lead sponsor
Yale University
Other
Eligibility
12 Years to 25 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)

NCT02865499
View directory record Official record
Conditions
Aging
Interventions
acarbose
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
70 Years to 95 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 2, 2026, 5:42 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 2, 2026, 5:42 AM EDT